---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-019884"
form_type: "8-K"
ticker: "RZLT"
cik: "0001509261"
company_name: "Rezolute, Inc."
filed_at: "2024-02-13T23:59:59+00:00"
generated_at: "2026-06-06T03:21:59.410133+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Rezolute reports Q2 FY2024 net loss $13.9M; initiates Phase 3 for RZ358 in cHI

## Summary
- Net loss of $13.9M for Q2 FY2024, compared to $13.6M same period prior year.
- Cash, cash equivalents and investments $96.0M as of Dec 31, 2023, down from $118.4M at June 30, 2023.
- Initiated sunRIZE Phase 3 study of RZ358 in congenital hyperinsulinism; topline results expected mid-2025.
- Completed enrollment in Phase 2 study of RZ402 for diabetic macular edema; topline data expected Q2 2024.
- Appointed Daron Evans as CFO, expanding leadership for late-stage development.

## SEC filing metadata
- accession: 0001104659-24-019884
- form_type: 8-K
- ticker: RZLT
- cik: 0001509261
- company_name: Rezolute, Inc.
- filed_at: 2024-02-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509261/000110465924019884/0001104659-24-019884-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509261/000110465924019884/tm245849d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-019884
- JSON: https://secwatch.observer/filing/0001104659-24-019884.json
- Plain text: https://secwatch.observer/filing/0001104659-24-019884.txt

## Key facts
- Earnings Releases
  Rezolute, Inc. reported second quarter of fiscal 2024 ended December 31, 2023 results: net income $13.9 million.
  - Period: second quarter of fiscal 2024 ended December 31, 2023
  - Net income: $13.9 million
  - Result: reported results
  source text: Net loss was $13.9 million for the second quarter of fiscal 2024, compared to $13.6 million for the same period in fiscal 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1509261/000110465924019884/0001104659-24-019884-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.